Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Volastra Therapeutics reports that the initial patient has been treated in the Phase I/II Clinical Study of VLS-1488, a unique KIF18A inhibitor in its innovative compound portfolio
3 November 2023
Volastra Therapeutics has begun dosing the first participant in a Phase I/II clinical trial of VLS-1488, which, along with sovilnesib, forms their portfolio of unique KIF18A inhibitors designed to treat solid tumors with high chromosomal instability.
Drug Insights
4 min read
Deep Scientific Insights on Levomepromazine's R&D Progress, Mechanism of Action, and Drug Target
3 November 2023
This article summarized the latest R&D progress of Levomepromazine, the mechanism of action for Levomepromazine, and the drug target R&D trends for Levomepromazine.
Valuable Targets
6 min read
Analysis on the Clinical Research Progress of FcRn Antagonists
3 November 2023
FcRn, or neonatal Fc receptor, is a crucial protein found in the human body that plays a significant role in the immune system and the pharmacokinetics of therapeutic antibodies.
Drug Insights
5 min read
An In-depth Analysis of Lisocabtagene maraleucel's R&D Progress and Mechanism of Action on Drug Target
3 November 2023
This article summarized the latest R&D progress of Lisocabtagene maraleucel, the Mechanism of Action for Lisocabtagene maraleucel, and the drug target R&D trends for Lisocabtagene maraleucel.
Latest Hotspot
3 min read
Allyx Therapeutics' primary compound, ALX-001, demonstrates safety and toleration through dosage testing and successfully engages with the brains of healthy seniors
3 November 2023
At the 16th Clinical Trials on Alzheimer's Disease convention in Boston on October 27, 2023, clinical-phase biotech firm Allyx Therapeutics revealed findings from their Phase 1a study of ALX-001, their orally administered, pioneering, highly-selective, synapse-focused, disease-modifying neurodegenerative treatment.
Drug Insights
4 min read
Moxonidine: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
3 November 2023
This article summarized the latest R&D progress of Moxonidine, the Mechanism of Action for Moxonidine, and the drug target R&D trends for Moxonidine.
Latest Hotspot
3 min read
RUBY's Phase III clinical trial using Jemperli (dostarlimab) and chemotherapy for endometrial cancer has successfully improved patient survival rates
3 November 2023
Clinical trial phase III of RUBY, using Jemperli (dostarlimab) with chemotherapy for treating endometrial cancer, successfully reaches endpoint in enhancing overall patient survival rate.
Drug Insights
4 min read
Loracarbef: Detailed Review of its Transformative R&D Success
3 November 2023
This article summarized the latest R&D progress of Loracarbef, the Mechanism of Action for Loracarbef, and the drug target R&D trends for Loracarbef.
Latest Hotspot
3 min read
NovelMed Initiates Phase II Trial of Anti-Bb Antibody (NM8074) for Untried PNH Patients: An Insight into the PNH Study Development
3 November 2023
NovelMed Therapeutics kicks off its Phase II trial for untreated Paroxysmal Nocturnal Hemoglobinuria (PNH) patients. The primary investigation will be on the anti-Bb antibody NM8074 through a comprehensive study, aiming to evaluate its safety and efficiency in PNH patients.
Drug Insights
4 min read
ExploringEbastine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
3 November 2023
This article summarized the latest R&D progress of Ebastine, the mechanism of action for Ebastine, and the drug target R&D trends for Ebastine.
Latest Hotspot
3 min read
Novartis's atrasentan trial in Phase III showed effective and notable proteinuria reduction in IgA nephropathy (IgAN) patients with high statistical significance
3 November 2023
Novartis published positive early results from the critical Phase III ALIGN trial midpoint evaluation, studying atrasentan, an oral ERA for treating people with IgA nephropathy.
Bio Sequence
2 min read
Biological Glossary | What is Exon?
3 November 2023
Exons are coding sections of an RNA transcript, or the DNA encoding it, that are translated into protein.